In December, the global market experienced a notable decline in Valsartan prices, extending the downward trajectory from November. This trend was primarily fueled by weak demand from end-user pharmaceutical and healthcare industries, coupled with an ample supply in the market. Additionally, the price drop was intensified by year-end inventory clearance efforts, as suppliers and distributors sought to offload older stock to make way for fresh inventory at the beginning of the new year. These combined factors created a favorable environment for price reductions, further pressuring the Valsartan market.
The decline in Valsartan prices in China can be attributed to a combination of factors, notably the softening economic conditions reflected in the country鈥檚 manufacturing sector. China&#xx;s official National Bureau of Statistics (NBS) Manufacturing PMI unexpectedly dropped to xx.x in December xxxx, signaling a slowdown after a period of expansion. Although the index still remained above the neutral xx...
